Biochemical recurrence-free and cancer-specific survival after radical prostatectomy at a single institution

Korean Journal of Urology

Volumn 51, Issue 12, 2010, Pages 836-842

  Kim, Seong Cheol ^a   Jeong, Ingab ^a   Song, Cheryn ^a   Hong, Jun Hyuk ^a   Kim, Choung Soo ^a   Ahn, Hanjong ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Prostatectomy; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE COURSE; FOLLOW UP; GLEASON SCORE; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT ASSESSMENT; PELVIS LYMPH NODE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL RATE;

EID: 78650901060     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2010.51.12.836     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 2003;170:S21-5.
3. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
4. Whittemore AS. Prostate cancer. Cancer Surv 1994;19-20:309-22.
5. The statistics report: the incidence of cancer on 2003-2005 and the survival rate on 1993-2005, http://www.ncc.re.kr (accessed Apr 1, 2009). National Cancer Center; 2009.
6. Song C, Ro JY, Lee MS, Hong SJ, Chung BH, Choi HY, et al. Prostate cancer in Korean men exhibits poor differentiation and is adversely related to prognosis after radical prostatectomy. Urology 2006;68:820-4.
7. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172:910-4. (Pubitemid 39096421)
8. Hammad FT. Radical prostatectomy. Ann N Y Acad Sci 2008;1138:267-77.
9. Reiner WG, Walsh PC. An anatomical approach to the surgical management of the dorsal vein and Santorini's plexus during radical retropubic surgery. J Urol 1979;121:198-200.
10. Murphy GP, Busch C, Abrahamsson PA, Epstein JI, McNeal JE, Miller GJ, et al. Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. Scand J Urol Nephrol Suppl 1994;162:7-42.
11. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74.
12. Song C, Kang T, Lee MS, Ro JY, Lee SE, Lee E, et al. Clinico-pathological characteristics of prostate cancer in Korean men and nomograms for the prediction of the pathological stage of the clinically localized prostate cancer: a multi-institutional update. Korean J Urol 2007;48:125-30.
13. Xu DD, Sun SD, Wang F, Sun L, Stackhouse D, Polascik T, et al. Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy. Urology 2009;74:654-8.
14. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528-34.
15. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
16. Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ Jr, Yossepowitch O, Vickers AJ, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27:4300-5.
17. Porter CR, Kodama K, Gibbons RP, Correa R Jr, Chun FK, Perrotte P, et al. 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. J Urol 2006;176:569-74. (Pubitemid 43927880)
18. Egawa S, Suyama K, Arai Y, Tsukayama C, Matsumoto K, Kuwao S, et al. Treatment outcome by risk group after radical prostatectomy in Japanese men. Int J Urol 2001;8:295-300.
19. Hsu YS, Wang JS, Wu TT. E-cadherin expression in prostate adenocarcinomas in Chinese and its pathological correlates. Urol Int 2004;73:36-40.
20. Khan MA, Han M, Partin AW, Epstein JI, Walsh PC. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology 2003;62:86-91.
21. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
22. Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, Elashoff D, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 2004;22:446-53.
23. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001;28:555-65.
24. Wright JL, Dalkin BL, True LD, Ellis WJ, Stanford JL, Lange PH, et al. Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality. J Urol 2010;183:2213-8.
25. Karakiewicz PI, Eastham JA, Graefen M, Cagiannos I, Stricker PD, Klein E, et al. Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology 2005;66:1245-50.
26. Pettus JA, Weight CJ, Thompson CJ, Middleton RG, Stephenson RA. Biochemical failure in men following radical retropubic prostatectomy: impact of surgical margin status and location. J Urol 2004;172:129-32.